Former Chief Medical Officer of Cardiovascular Systems Joins Big Sky Biomedical Incubator

Dr. Ryan Egeland [Image courtesy of Egeland]

Dr. Ryan Egeland – who served as Cardiovascular Systems’ chief medical officer until earlier this month – has joined the Big Sky Biomedical incubator as chief executive.

“Big Sky Biomedical was founded to enhance innovation and early-stage development in some of the fastest growing segments of healthcare, including neurovascular, cardiac structural and regenerative medicine,” Egeland said in a statement. press release issued today.

“I am extremely excited to apply my scientific, medical and business experience to our portfolio companies in a much broader and deeper capacity,” Egeland said. “Alongside our exceptional teams of engineers, scientists, operators and physician partners, I look forward to addressing large underserved patient populations and significant unmet clinical needs with technologies. compelling and differentiated.”

Founded by a group of serial medical device entrepreneurs in the cardiovascular field, Big Sky Biomedical describes itself as a highly specialized incubator focused on developing rapid, capital-efficient therapies.

“Ryan brings deep cross-functional expertise to our agile, capital-efficient businesses,” said JC Sun, founding partner of the incubator. “With his guidance and operational involvement, not only am I very confident in our ability to execute in the near term, but I am extremely optimistic about Big Sky’s potential to streamline value creation from zero to one, establishing a new standard for accelerating next-level medical medicine. device design and development.

Prior to his nearly five years at Cardiovascular Systems, Egeland spent half a decade as an executive at Medtronic. He received his medical degree from Harvard Medical School and was a Rhodes Scholar at the University of Oxford, where he earned his Ph.D. and MBA.

Cardiovascular Systems, based in St. Paul, Minn., announced on March 4 that Dr. Jeffery W. Chambers was its new chief medical officer. Chambers was the principal investigator of the Orbit II study – the pivotal trial supporting pre-marketing approval for the use of orbital atherectomy in coronary arteries.